DNA-driven enhancement of ocular drug delivery: formulation and evaluation of diclofenac-loaded HPMC films.

IF 3.6 4区医学 Q2 ENGINEERING, BIOMEDICAL

Journal of Biomaterials Science, Polymer Edition Pub Date : 2025-10-09 DOI:10.1080/09205063.2025.2570367

Pratikeswar Panda, Rajaram Mohapatra

{"title":"DNA-driven enhancement of ocular drug delivery: formulation and evaluation of diclofenac-loaded HPMC films.","authors":"Pratikeswar Panda, Rajaram Mohapatra","doi":"10.1080/09205063.2025.2570367","DOIUrl":null,"url":null,"abstract":"The use of DNA in ocular drug delivery as a polymeric bio additive has potential in modulating the physicochemical properties of the film former to sustain drug release. This study reports the development and evaluation of DNA-incorporated HPMC film matrices to improve the ocular delivery and therapeutic efficacy of Diclofenac. Four formulations (DH1-DH4) were prepared with increasing DNA ratios (0, 1:0.01, 1:0.02, and 1:0.03). FTIR, DSC, and XRD analyses confirmed amorphous dispersion of Diclofenac within the matrix without chemical degradation, while SEM revealed a uniform and smooth film morphology. DNA incorporation significantly enhanced hydration (DH4: 620 ± 31.45%), transparency (DH4: ∼55% transmittance at 800 nm), and matrix erosion (DH4: 432 ± 30.25%), which contributed to improved drug release (DH4: 88.3 ± 2.6% at 300 min) and permeation (DH4: 89.5 ± 3.2% at 12 h). Kinetic modeling indicated a strong fit to the Higuchi model (R2 = 0.95-0.99), while Korsmeyer-Peppas n values (0.37-0.52) suggested anomalous (non-Fickian) diffusion mechanisms. Stability studies confirmed high moisture retention (DH4: 96 ± 1.5%) and tensile strength (DH4: 20 ± 1.5 MPa) over three months, ensuring the formulation's shelf stability. Antioxidant assays demonstrated superior activity in DH4, with DPPH (IC50: 32 ± 1.8 μM) and H2O2 scavenging (IC50: 39 ± 1.7 μM). Overall, Diclofenac-DNA-HPMC films, particularly DH4, exhibit significant potential for effective ocular drug delivery by enhancing the therapeutic performance while maintaining stability and patient compliance.","PeriodicalId":15195,"journal":{"name":"Journal of Biomaterials Science, Polymer Edition","volume":" ","pages":"1-23"},"PeriodicalIF":3.6000,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biomaterials Science, Polymer Edition","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1080/09205063.2025.2570367","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}

引用次数: 0

Abstract

The use of DNA in ocular drug delivery as a polymeric bio additive has potential in modulating the physicochemical properties of the film former to sustain drug release. This study reports the development and evaluation of DNA-incorporated HPMC film matrices to improve the ocular delivery and therapeutic efficacy of Diclofenac. Four formulations (DH1-DH4) were prepared with increasing DNA ratios (0, 1:0.01, 1:0.02, and 1:0.03). FTIR, DSC, and XRD analyses confirmed amorphous dispersion of Diclofenac within the matrix without chemical degradation, while SEM revealed a uniform and smooth film morphology. DNA incorporation significantly enhanced hydration (DH4: 620 ± 31.45%), transparency (DH4: ∼55% transmittance at 800 nm), and matrix erosion (DH4: 432 ± 30.25%), which contributed to improved drug release (DH4: 88.3 ± 2.6% at 300 min) and permeation (DH4: 89.5 ± 3.2% at 12 h). Kinetic modeling indicated a strong fit to the Higuchi model (R² = 0.95-0.99), while Korsmeyer-Peppas n values (0.37-0.52) suggested anomalous (non-Fickian) diffusion mechanisms. Stability studies confirmed high moisture retention (DH4: 96 ± 1.5%) and tensile strength (DH4: 20 ± 1.5 MPa) over three months, ensuring the formulation's shelf stability. Antioxidant assays demonstrated superior activity in DH4, with DPPH (IC₅₀: 32 ± 1.8 μM) and H₂O₂ scavenging (IC₅₀: 39 ± 1.7 μM). Overall, Diclofenac-DNA-HPMC films, particularly DH4, exhibit significant potential for effective ocular drug delivery by enhancing the therapeutic performance while maintaining stability and patient compliance.

查看原文本刊更多论文

dna驱动增强眼部药物传递：双氯芬酸负载HPMC薄膜的制备和评价。

将DNA作为一种高分子生物添加剂用于眼部给药，有可能调节膜前体的物理化学性质以维持药物释放。本研究报道了dna结合HPMC膜基质的开发和评价，以改善双氯芬酸的眼部输送和治疗效果。分别以DNA比为0、1:0.01、1:0.02、1:0.03分别制备DH1-DH4 4种配方。FTIR， DSC和XRD分析证实了双氯芬酸在基质内的无定形分散，没有化学降解，而SEM显示了均匀光滑的膜形态。DNA结合显著提高水化(DH4: 620 ± 31.45%),透明度(DH4:∼55%透光率在800 海里),和矩阵侵蚀(DH4: 432±30.25%),这有助于改善药物释放(DH4: 88.3 ± 2.6%至300 min)和渗透(DH4: 89.5 ±3.2% 12 h)。动力学模型与Higuchi模型拟合良好（R2 = 0.95-0.99），Korsmeyer-Peppas n值（0.37-0.52）表明存在异常（非fickian）扩散机制。稳定性研究证实了三个月的高保湿率（DH4: 96 ± 1.5%）和抗拉强度（DH4: 20 ± 1.5 MPa），确保了配方的货架稳定性。抗氧化实验表明，对DH4具有较强的抗氧化活性，对DPPH （IC50: 32±1.8 μM）和H2O2清除能力（IC50: 39 ± 1.7 μM）。总的来说，双氯芬酸- dna - hpmc膜，特别是DH4，通过提高治疗性能，同时保持稳定性和患者依从性，显示出有效眼部给药的巨大潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Biomaterials Science, Polymer Edition 工程技术-材料科学：生物材料

CiteScore

7.10

自引率

5.60%

发文量

117

审稿时长

1.5 months

期刊介绍： The Journal of Biomaterials Science, Polymer Edition publishes fundamental research on the properties of polymeric biomaterials and the mechanisms of interaction between such biomaterials and living organisms, with special emphasis on the molecular and cellular levels. The scope of the journal includes polymers for drug delivery, tissue engineering, large molecules in living organisms like DNA, proteins and more. As such, the Journal of Biomaterials Science, Polymer Edition combines biomaterials applications in biomedical, pharmaceutical and biological fields.